PRISM-TB is an international, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, noninferiority Phase 3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB).
The trial objective is to evaluate whether stratified medicine treatment strategies for FQ-S MDR/RR-TB, defined by a pre-specified risk stratification algorithm, have noninferior efficacy to a one-size-fits-all control regimen (the local standard-of-care [SOC] regimen consistent with preferred regimen(s) in international guidelines), as measured by TB-related unfavorable outcomes at Week 73.

Start Date01 Oct 2026

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NCT03244072

/ Not yet recruitingPhase 2/3

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Start Date01 Jun 2025

Sponsor / Collaborator

Zion Therapeutics, LLC

NCT06846866

/ Not yet recruitingPhase 1

A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positivecontrolled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.

Start Date25 Feb 2025

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Moxifloxacin Hydrochloride

100 Translational Medicine associated with Moxifloxacin Hydrochloride

100 Patents (Medical) associated with Moxifloxacin Hydrochloride

12,702

Literatures (Medical) associated with Moxifloxacin Hydrochloride

31 Dec 2025·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

Author: Guedj, Jeremie ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; de Gunzburg, Jean ; Olivares, Carlos ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

01 Jul 2025·Separation and Purification Technology

Synergistic doped and loaded strategies to modify WO3 nanoflowers for efficient photocatalytic degradation of antibiotics through reactive oxygen species regulation

Author: Liu, Wen ; Li, Xiuze ; Yang, Xudong ; Qi, Juanjuan ; Guo, Liangyan

Developing an effective and powerful photocatalyst is important to its practical application in water treatment area, like emerging contaminants removal in water.Herein, through a synergistic strategy of N-doping and carbon quantum dots (CQDs)-loading on WO₃ nanoflowers, CQDs/N-WO₃ was designed, which exhibited excellent photocatalytic performance due to modulated electronic structure.Both exptl. characterization and theor. calculation confirmed that the synergistic effect accelerated the electron transfer ability from O2p to W5d, thus promoting the photogenerated electron and hole separation efficiency owing to the increased W5d orbital electron d.The optimum photocatalyst achieved 100 % removal of gatifloxacin (GAT) with a high reaction rate constant (k₁) of 0.055 min^-1 in 60 min under simulated solar light.Moreover, quenching experiment and radical detection demonstrated that the main reactive oxygen species (ROS) changed from ^•OH (WO₃ and N-WO₃) to O^•-₂ (CQDs/N-WO₃) for GAT removal.D. functional theory (DFT) calculation based on Fukui index further indicated the reactive sites of GAT were available for electrophilic attack.The internal mechanism was also deduced that after N doped and CQDs loaded on WO₃, narrowed band gap and increased utilization of visible light were observedMoreover, the high electron d. of N sites was more conducive to hole capture, and CQDs enhanced the electron transport as electron acceptor and transporter.The synergistic strategy of doping and loading opens a new perspective for modulating the electronic structure of catalysts, and provides a reference for regulating the ROS types in Fenton-like reactions for the removal of emerging contaminants in water.

01 Jun 2025·Separation and Purification Technology

Novel polymeric membranes based on green reduced graphene oxide for the nanofiltration of emerging contaminants from water in a ternary system

Author: Pinto, Juliah Camargo ; Prediger, Patricia ; Morais da Silva, Paula Mayara ; Dantas, Renato Falcao ; Malvestiti, Jacqueline Aparecida ; da Silva, Paula Mayara Morais ; Camparotto, Natalia Gabriele ; Mastelaro, Valmor Roberto

Polymeric membranes containing reduced graphene oxide (rGO) have demonstrated efficacy in the remediation of contaminated water.The objective of this study was to examine the impact of the morphol. and physicochem. properties of polyacrylonitrile membranes (hPAN) containing rGO on their filtration and adsorption performance.The rGO was prepared via a green route (g-rGO), and the filtration experiments applied the removal of emerging contaminants in a ternary system that simulates real conditions.The incorporation of g-rGO into the membrane resulted in the formation of a thinner finger-like sublayer, an increased in the membrane's roughness, and an enhancement in the pure water flux.The batch experiments revealed adsorption rates of 72%, 55%, 75%, 96%, and 80% for ciprofloxacin (CIP), moxifloxacin (MOX), and levofloxacin (LEV), Cu(II) and Zn(II), resp.The adsorption rate for CIP and MOX increased by 151% and 87.5%, resp., in comparison to the pristine hPAN membrane.In the filtration experiments conducted in a ternary system, the membrane hPAN@g-rGO5 exhibited a rejection rate of 62%, 59%, and 68% for acetaminophen, atrazine, and sulfamethoxazole, resp.The d. functional theory (DFT) study indicated that sulfamethoxazole was the most removed emerging contaminant of the ternary system, primarily due to its higher size and the presence of π-π interactions and hydrogen bonding.

News (Medical) associated with Moxifloxacin Hydrochloride

06 Feb 2025

·www.drugs.com

Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB

THURSDAY, Feb. 6, 2025 -- Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin -resistant tuberculosis , according to a study published in the Jan. 30 issue of the New England Journal of Medicine . Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points. The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar. "The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis," the authors write. Two authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3Clinical Result

13 Jan 2025

·www.drugs.com

Shorter Treatment Regimens Recommended for Tuberculosis

MONDAY, Jan. 13, 2025 -- In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine , updated recommendations are presented for the treatment of tuberculosis (TB) in children and adults. Jussi J. Saukkonen, M.D., from the Boston Veterans Administration Health Care System, and colleagues updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies are available on a regular basis. The evidence was reviewed and recommendations made. The authors note that new recommendations for drug-susceptible TB include use of a novel four-month regimen for individuals with pulmonary TB and a shortened four-month regimen, instead of the six-month regimen, for nonsevere TB in children. Use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin are included as recommendations for drug-resistant TB. For adolescents aged 14 years and older and adults with rifampin-resistant pulmonary TB, a six-month bedaquiline, pretomanid, and linezolid regimen is as efficacious and safe as the current 15-month or longer regimen. "There has been a quest and concerted effort to develop shorter treatments for TB, after decades of little drug development," Saukkonen said in a statement. "With recent studies we have been able to shorten the regimen durations for both drug-susceptible and drug-resistant TB for most patients, down to four and six months, respectively." Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3

11 Dec 2024

·www.businesswire.com

Meitheal Pharmaceuticals Grows Specialty Biopharmaceuticals Portfolio with Exclusive Commercial Licensing Agreement for XENLETA® (lefamulin acetate)

CHICAGO--( BUSINESS WIRE )--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic, fertility, biologic, and branded injectable products, announced it has secured exclusive commercial rights in the U.S. to XENLETA ® (lefamulin acetate) through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industrial Co., Ltd. (HKF). XENLETA ® belongs to a new class of novel antibiotics and is approved in intravenous and oral formulations in the U.S. and multiple other countries for the treatment of community-acquired bacterial pneumonia (CABP) in adults. HKF has acquired global rights to XENLETA ® (with the exception of Greater China) from Nabriva Therapeutics. Through the acquisition, HKF has obtained substantially all global assets related to XENLETA ® , including results of development and regulatory activities. “The licensing of XENLETA ® bolsters our portfolio of novel antibiotics and reflects our focus on addressing the growing issue of antimicrobial resistance,” said Tom Shea, Chief Executive Officer of Meitheal. “As the first approved medicine of an entirely new class of antibiotics, XENLETA ® is an innovative therapeutic option that will be available to the patients affected by CABP and has been shown to be active against various bacterial strains. We look forward to leveraging our end-to-end expertise in biopharmaceutical development and commercialization to bring this important therapeutic to patients in need.” XENLETA ® is a first-in-class semi-synthetic pleuromutilin antibiotic. As a monotherapy offering a complete spectrum of coverage for the main CABP pathogens and with a low propensity for the development of bacterial resistance, XENLETA ® represents a critical step in addressing the growing global public health crisis of antimicrobial resistance (AMR) and supports the principles of antimicrobial stewardship. “Antimicrobial resistance, unfortunately, undermines the treatment paradigms of many infectious diseases globally, leading to poor patient outcomes and increased costs to healthcare systems,” said Brett Novak, Meitheal’s Senior Vice President of Commercial Operations. “XENLETA ® provides a unique and well-tolerated product profile for the more than five million annual cases of CABP in the U.S., where it has the potential to serve as a first-line monotherapy option in both the inpatient and outpatient settings. We are pleased that this agreement will allow us to unlock synergies with our existing franchises and deliver critical medicines that address large gaps in the antibiotic treatment landscape.” Global approvals of XENLETA ® in CABP are based on the results of two global, pivotal Phase 3 trials, LEAP 1 and LEAP 2, in which XENLETA ® met all primary endpoints. Meitheal recently added the first anti-infective to its portfolio through an exclusive commercialization agreement with HKF—CONTEPO™. Meitheal will leverage its new aligned-to-CONTEPO ™ marketing, sales, and medical science liaison teams to support the launch of XENLETA ® , which shares similar hospital call points. Meitheal will further establish practice-based support for key prescribers and patients that could benefit from XENLETA ® . “We are pleased to have acquired the rights to XENLETA ® and look forward to supporting Meitheal as it delivers this important medication to patients in the U.S.,” said Eric Tang, President of HKF. “We are committed to supporting Meitheal’s work to deliver accessible, sustainable, and innovative healthcare solutions and we remain focused on continuing to invest in the research, development, and commercialization of branded pharmaceuticals to achieve this goal.” HKF and its related entities have invested over $300 million in capital and research and development in recent years to support sustainable product supply across key focus areas, including branded biopharmaceuticals. The licensing agreement for XENLETA ® adds a third branded biopharmaceutical and first on-market branded product to Meitheal’s portfolio. ABOUT COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) Pneumonia is an infection of the lung that can be serious and fatal, especially among older adult patients with comorbidities. CABP is among the most common types of pneumonia, with five million cases in the U.S. each year. 1 In the U.S., CABP is the leading cause of infection-related death 2 and the fourth leading cause of hospitalization, 3 a setting where mortality rates are approximately 15% 4 . Certain bacteria that cause CABP have become resistant to one common antibiotic, macrolides, at a rate on average of 50%. 5 The U.S. FDA has also issued multiple warnings about the resistance of one current class of CABP treatments called fluoroquinolones. 6 Antimicrobial resistance (AMR) is a top global public health threat that creates challenges treating infections and performing medical procedures and increases the risk of death and disability. 7 Novel antibiotics that kill bacteria, including those that cause CABP, in a different way are essential to addressing AMR. 8 ABOUT XENLETA ® XENLETA ® (lefamulin acetate) is a first-in-class, semi-synthetic pleuromutilin antibiotic for systemic administration in humans. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETA ® ’s binding occurs with high affinity, high specificity, and at molecular sites that are different than other antibiotic classes. Two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP demonstrated XENLETA ® ’s efficacy. In these trials, XENLETA ® was compared with moxifloxacin, and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA ® had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. CONTRAINDICATIONS XENLETA ® is contraindicated in patients with known hypersensitivity to lefamulin, pleuromutilin class drugs, or any of the components of XENLETA ® . Concomitant use of XENLETA ® tablets with CYP3A substrates that prolong the QT interval is contraindicated. WARNINGS AND PRECAUTIONS QT Prolongation: Avoid use in patients with known QT prolongation, ventricular arrhythmias including torsades de pointes, and patients receiving drugs that prolong the QT interval such as antiarrhythmic agents. Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. Clostridioides difficile-associated Diarrhea: Evaluate patients who develop diarrhea. ADVERSE REACTIONS The most common adverse reactions associated with XENLETA ® Injection include administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia and headache. The most common adverse reactions associated with XENLETA ® Tablets include diarrhea, nausea, vomiting, hepatic enzyme elevation. Please see Full Prescribing Information for more information. ABOUT MEITHEAL PHARMACEUTICALS, INC. Founded in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. Food and Drug Administration (FDA)-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of October 2024, Meitheal, directly or through its partners, has 18 products in the research and development phase, 6 additional products planned for launch in 2024, and 21 products under review by the FDA. Meitheal’s mission is to provide easy access to fairly-priced products through robust manufacturing, consistent supply, and rapid response to our customers’ needs. Ranked #2 in 2024 on Crain’s Fast 50 in Chicago, and in the top 100 of Crain’s Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for — working together toward a common goal, for the greater good. Learn more about who we are and what we do at www.meithealpharma.com . ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF) Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Company, founded in 2010. ABOUT NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL COMPANY (NKF) Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of the world’s leading manufacturers of heparin-related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA-approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. NKF is publicly listed on the Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. ABOUT NABRIVA THERAPEUTICS PLC Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. FDA approval for XENLETA ® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics also previously developed CONTEPO™ (fosfomycin for injection), a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI). ___________________________ 1 National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) 2009 -2010. https://archive-cdc-gov.libproxy1.nus.edu.sg/#/details?url=https://www-cdc-gov.libproxy1.nus.edu.sg/nchs/data/ahcd/combined_tables/2009-2010_combined_web_table01.pdf (Last Accessed December 4, 2024). 2 el Bcheraoui C, Mokdad AH, Dwyer-Lindgren L, et al. Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014. JAMA.2018;319(12):1248–1260. doi:10.1001/jama.2018.2089. 3 McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. Hospitals, 2018: Statistical Brief, no 277. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality. 2021. https://hcup-us.ahrq.gov/reports/statbriefs/sb277-Top-Reasons-Hospital-Stays-2018.pdf . 4 2017 CHARTBOOK STATIC ANALYSES -Trends in mortality rates following admission for acute myocardial infarction, chronic obstructive pulmonary disease, heart failure, pneumonia, and acute ischemic stroke. Prepared for CMS by Yale New Haven Health Services Corporation -Center for Outcomes Research and Evaluation (YNHHSC/CORE) September 2017. 5 Classi P, Landsman-Blumberg P, Carroll C, et al. The relationship between macrolide-resistant streptococcus pneumoniae and treatment failure in adults with community-acquired pneumonia by CDC region in the United States. Abstract J03. In: Meeting abstracts, Academy of Managed Care Pharmacy Nexus 2016; October 3-6, 2016; National Harbor, MD. 6 Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics-risks-mental-health-and-low-blood-sugar-adverse . Accessed December 4, 2024. 7 World Health Organization. Antimicrobial resistance. https://www-who-int.libproxy1.nus.edu.sg/news-room/fact-sheets/detail/antimicrobial-resistance . Accessed December 4, 2024. 8 Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013, US Department of Health and Human Services.

Phase 3License out/inDrug ApprovalClinical Result

100 Deals associated with Moxifloxacin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00874	Moxifloxacin Hydrochloride	J01MA14 S01AE07	DB00218

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Respiratory Tract Infections	China	Bayer Vital GmbH	11 Aug 2009
Blepharitis	Japan	Novartis Pharma AG	26 Jul 2006
Conjunctivitis	Japan	Novartis Pharma AG	26 Jul 2006
Corneal Ulcer	Japan	Novartis Pharma AG	26 Jul 2006
Dacryocystitis	Japan	Novartis Pharma AG	26 Jul 2006
Hordeolum	Japan	Novartis Pharma AG	26 Jul 2006
Keratitis	Japan	Novartis Pharma AG	26 Jul 2006
Acute Bronchitis	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Bacterial Infections	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Pharyngolaryngitis	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Pneumonia	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
respiratory tract; infection, chronic	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Secondary infection	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Sinusitis	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Skin and skin structure infections	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Tonsillitis	Japan	Bayer Yakuhin Ltd.	11 Oct 2005
Conjunctivitis, Bacterial	United States	Harrow, Inc.	15 Apr 2003
Acute bacterial sinusitis	United States	Bayer Pharma AG	27 Apr 2001
Bronchitis, Chronic	United States	Bayer Pharma AG	27 Apr 2001
Community Acquired Pneumonia	United States	Bayer Pharma AG	27 Apr 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-complicated skin and skin structure infection	Phase 3	United States	Bayer HealthCare Pharmaceuticals, Inc.	22 Nov 2005
Bronchitis, Chronic	Phase 3	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 Dec 1999
Community Acquired Pneumonia	Phase 3	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 Dec 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06215521 (CTgov)	Phase 1	-	31	Pirtobrutinib (Treatment A: 900 mg Pirtobrutinib)	dfylnvohnp(jwccouklaa) = mxljzjuazd bteavgftjd (bfjzbkxbkb, bqatqstzjs - ptecydbyzm) View more	-	24 Feb 2025
				Placebo+Pirtobrutinib (Treatment B: 900 mg Pirtobrutinib Matched Placebo)	pnwidupzuu(xryblhzcsh) = ghhjcqviyo ysrxspumeo (ioxhhtzwzl, iujnffkvmz - kwohxcggbk) View more
NCT04179500 (PaSEM, CTgov)	Phase 2	Multidrug resistant pulmonary tuberculosis \| Tuberculosis, Multidrug-Resistant	26	BPaMZ (BPaMZ)	sldggfwzmq(qvqbrjgiet) = aubftplugi zqhcjztjmb (ltfxzfohfr, nxcjgialgr - neziovaisv) View more	-	19 Sep 2024
				moxifloxacin+bedaquiline+pyrazinamide (BPaMZ Baseline)	pmphbayape(vqbwawzzwh) = kfruouqyze rfnjrwurdn (yghuanjpgg, zpyishhaho - tgakwieraw) View more
NCT02807207 (MPN-302, SOHO2024)	Phase 1	-	42	Moxifloxacin 400 mg	wlzypkkwin(orlybebtcu) = 29.3% fonitmeaes (thtkhcgmrg ) View more	Positive	04 Sep 2024
NCT02589782 (TB-PRACTECAL, Pubmed) Manual	Phase 2/3	Extensively Drug-Resistant Tuberculosis	552	rifampicin (Standard care)	sztmwaerbh(cgohokqutv) = brqcrzvoyf axkbyzhepo (lhmstrrxyy ) View more	Positive	01 Feb 2024
				rifampbedaquilinepretomanidlinezolidmoxifloxacin (BPaLM)	sztmwaerbh(cgohokqutv) = bjjqwohqyu axkbyzhepo (lhmstrrxyy ) View more
NCT03338621 (SimpliciTB, CTgov)	Phase 2/3	Multidrug resistant pulmonary tuberculosis \| Tuberculosis, Multidrug-Resistant	455	ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR)	zbiivdkbie(wlxoncolbh) = igxbjamvjl gxckhigior (yaauibaefb, tgpcaiayku - vzgqgiimmo) View more	-	08 Nov 2023
				4BPaMZ (Drug Sensitive-TB 4BPaMZ)	zbiivdkbie(wlxoncolbh) = vmnuipnplb gxckhigior (yaauibaefb, xngyqjarwe - azlmpjiulo) View more
APAO2023	Not Applicable	-	131	Topical Levofloxacin 1.5%	qszlrnjbzh(vjztdikkwz) = ecuxksicvt xrxoyhgpxd (znlnkaugsy ) View more	Positive	23 Feb 2023
				Topical Moxifloxacin Hydrochloride 0.5%	qszlrnjbzh(vjztdikkwz) = smscttznec xrxoyhgpxd (znlnkaugsy ) View more
NCT02531438 (OPTIC, Pubmed)	Phase 3	Community-acquired bacterial pneumonia	774	Omadacycline	(mxshohleht) = uzruwlxdwz suuhuwrtdt (lthwupbudg )	Positive	01 Jan 2023
				Moxifloxacin	(mxshohleht) = lesfqgzphb suuhuwrtdt (lthwupbudg )
ERS2022	Not Applicable	-	-	Moxifloxacin	jfvckorhyq(kyqwneejca) = vxyjcegetq mxmubagjxh (dtghjnadyd )	-	04 Sep 2022
				Silver nanoparticles	jfvckorhyq(kyqwneejca) = efidqxkgml mxmubagjxh (dtghjnadyd )
EURETINA2022	Not Applicable	Endophthalmitis	-	moxifloxacin (Before prophylactic ICM)	pvffvodvhl(qwnxjafnoy) = ayjmbpbqmw wibopfpqbh (ptuidxbczx ) View more	-	01 Sep 2022
				moxifloxacin (After prophylactic ICM)	pvffvodvhl(qwnxjafnoy) = sqakloysjm wibopfpqbh (ptuidxbczx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis